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Abstract
Background: Peripheral blood interferon-gamma release assays (IGRAs) have sub-optimal sensitivity and specificity for
diagnosis of active pulmonary tuberculosis (TB). However, assessment of local immune responses has been reported to
improve the accuracy of TB diagnosis.
Methods: We enrolled HIV-infected adults with cough $2 weeks’ duration admitted to Mulago Hospital in Kampala, Uganda
and referred for bronchoscopy following two negative sputum acid-fast bacillus smears. We performed an ELISPOT-based
IGRA (T-SPOT.TBH, Oxford Immunotec, Oxford, UK) using peripheral blood and bronchoalveolar lavage (BAL) fluid
mononuclear cells, and determined the accuracy of IGRAs using mycobacterial culture results as a reference standard.
Results: 94 HIV-infected patients with paired peripheral blood and BAL IGRA results were included. The study population
was young (median age 34 years [IQR 28–40 years]) and had advanced HIV/AIDS (median CD4+ T-lymphocyte count 60
cells/ml [IQR 22–200 cells/ml]). The proportion of indeterminate IGRA results was higher in BAL fluid than in peripheral blood
specimens (34% vs. 14%, difference 20%, 95% CI 7–33%, p=0.002). BAL IGRA had moderate sensitivity (73%, 95% CI 50–
89%) but poor specificity (48%, 95% CI 32–64%) for TB diagnosis. Sensitivity was similar (75%, 95% CI 57–89%) and
specificity was higher (78%, 95% CI 63–88%) when IGRA was performed on peripheral blood.
Conclusions: BAL IGRA performed poorly for the diagnosis of smear-negative TB in a high HIV/TB burden setting. Further
studies are needed to examine reasons for the large proportion of indeterminate results and low specificity of BAL IGRA for
active TB in high HIV/TB burden settings.
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Introduction
Interferon-gamma release assays (IGRAs) are being used
increasingly for the detection of Mycobacterium tuberculosis (MTB)
infection. Commercial ELISA- and ELISPOT-based assays that
detect interferon-gamma release following overnight stimulation
with MTB-specific antigens (Early Secreted Antigen Target-6
[ESAT-6] and Culture Filtrate Protein-10 [CFP-10]) are now
recommended as an alternative to the tuberculin skin test for
targeted testing of individuals for latent tuberculosis (TB) infection.
[1,2] However, the diagnostic accuracy of blood IGRAs for active
TB has been disappointing, with sub-optimal sensitivity, especially
among the immunocompromised, and low specificity, especially in
high TB incidence areas, identified as particular concerns. [3,4].
Assessing MTB-specific immune responses at the site of disease
(i.e., the lungs) may improve IGRA performance for diagnosis of
active pulmonary TB. T-cells secreting IFN-c following stimula-
tion with either purified protein derivative (PPD) or M. TB-specific
antigens (ESAT-6 and CFP-10) have been detected at 10- to 100-
fold higher frequency in bronchoalveolar lavage (BAL) fluid
compared to peripheral blood specimens in patients with
pulmonary TB [5,6], which may enhance the sensitivity of
IGRAs. In addition, a lower ratio of central memory T-cells to
effector T-cells in the lung may increase the specificity of
immunologic assays for active disease. [7] In support of these
hypotheses, a prospective, multi-center study of 347 HIV-un-
infected TB suspects in Europe found BAL IGRA superior to
blood IGRA, the tuberculin skin test, and nucleic acid amplifica-
tion tests for the diagnosis of smear-negative pulmonary TB. [8].
Although bronchoscopy with BAL is unavailable in many TB
and HIV endemic settings, where it is available, it does improve
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Thus, we conducted a prospective study to evaluate the diagnostic
accuracy of BAL IGRA, and to compare BAL to peripheral blood
IGRA, in a country with high TB and HIV prevalence.
Methods
Ethics Statement
Institutional review boards at Makerere University, Mulago
Hospital, the Uganda National Council for Science and Technol-
ogy, and the University of California, San Francisco approved the
study protocol, and all patients provided written informed consent
for study participation.
Study Population
We prospectively enrolled consecutive HIV-infected patients
with suspected pulmonary TB who were sputum acid-fast bacillus
(AFB) smear-negative and referred for bronchoscopy at Mulago
Hospital in Kampala, Uganda. We excluded patients from the
analysis if TB status could not be established due to mycobacterial
culture contamination (at least two negative cultures were required
to exclude TB) or if blood or BAL IGRA testing was not
performed.
Patient Evaluation and Sample Collection
We administered a standardized questionnaire and reviewed
hospital records to collect demographic and clinical information,
including confirmation of HIV status recorded through the
Mulago Hospital voluntary counseling and testing program. We
collected blood samples for IGRA testing and measurement of
CD4+ T-lymphocyte count and two sputum samples for Low-
enstein-Jensen culture, as previously described. [10] Bronchoscopy
was performed for clinical indications and patients were consented
in accordance with standard clinical protocols. Bronchoscopy was
performed by clinical investigators (WW, SY, AC, JLD) according
to a standardized protocol that included collection of BAL fluid.
[11] Briefly, bronchoscopists performed BAL by wedging the tip of
the bronchoscope into the sub-segment of lung with the greatest
radiographic abnormality, instilled sterile normal saline (0.9%) in
serial 25 mL aliquots (up to a maximum of 125 mL), and aspirated
fluid until at least 50 mL were returned. Study technicians
immediately prepared at least 20 mL of BAL fluid for IGRA
testing, as described below.
IGRAs
Trained laboratory technicians at the Joint Clinical Research
Centre (JCRC) blinded to patients’ clinical status performed blood
and BAL IGRAs. Peripheral blood mononuclear cells (PBMCs)
were isolated using Ficoll-hypaque gradient centrifugation. BAL
fluid mononuclear cells (BALMCs) were obtained by passing the
sample through a 50 micron nylon mesh filter, pelleting the sample
by centrifugation (4506G for 10 minutes), and re-suspending the
pellet in R10 culture medium. PBMC and BALMC count and
viability were determined using a Guava automated counter
(Guava Technologies, Hayward, CA). Blood and BAL IGRAs
were performed using a commercially-available, enzyme-linked
immunospot (ELISPOT)-based assay (T-SPOT.TBH, Oxford
Immunotec, Oxford, UK) according to the manufacturer’s
guidelines for peripheral blood assays. Spot-forming cells (SFCs)
were counted using an automated ELISPOT reader (Immunospot
Analyzer, Cellular Technologies, Ltd. Cleveland, OH).
For the primary analysis, we interpreted peripheral blood IGRA
results according to manufacturer-recommended criteria and BAL
fluid IGRA results according to criteria published by the
Tuberculosis Network European Trials Group (TB NET). [8]
We also performed secondary analyses in which we classified BAL
IGRA results using alternative classification schemes that did not
exclude samples with high background interferon-gamma secre-
tion. First, as reported for in-house assays, we classified BAL
IGRA results as positive if the number of SFCs in either antigen-
stimulated well was at least two standard deviations above the
background control plus 5 SFCs. [12] Next, we analyzed BAL
IGRA results based on the ratio of SFCs between antigen-
stimulated wells and the background control well plus 5 SFCs.
Outcome Classification
We defined the reference standard for active TB as at least one
positive mycobacterial culture result on any sputum or BAL fluid
specimen (culture-positive TB). Cultures were interpreted without
knowledge of IGRA results.
Statistical Analysis
We performed bivariate analyses using the Fisher’s exact test for
dichotomous variables and the Mann-Whitney rank-sum test for
continuous variables. We compared median SFC counts between
BAL and blood IGRAs using the Wilcoxon matched-pairs signed-
ranks test. We calculated sensitivity and specificity of IGRAs using
mycobacterial culture results as a reference standard, and
compared sensitivity and specificity differences between BAL
and blood IGRAs using McNemar’s test. We determined the area
under the curve (AUC) using receiver operating characteristic
(ROC) analysis to evaluate the diagnostic utility of BAL IGRA at
various cut-points based on the ratio of SFCs in the antigen-
stimulated wells and the negative control well. We performed all
analyses using STATA 11.0 (Stata Corporation, College Station,
Texas), with the level of significance specified in reference to a two-
tailed, type I error (p-value) less than 0.05.
Results
Study Population
Of 110 HIV-infected patients referred for bronchoscopy
between June 2009 and December 2010, 6 patients who declined
the procedure and 10 patients for whom blood samples were not
collected were excluded from the analysis (Figure 1). Baseline
characteristics (gender, age, antiretroviral use, and CD4+ T-
lymphocyte count) were not significantly different between
excluded and included patients (p.0.2 for all comparisons). Of
the 94 included patients, 50 (53%) were women and the median
age was 34 years (IQR 28–40 years) (Table 1). The study
population had advanced HIV/AIDS (median CD4+ T-lympho-
cyte count 60 cells/ml [IQR 22–200 cells/ml]), but only 15 (16%)
patients were receiving anti-retroviral therapy. The reference
standard outcome of culture-positive TB was confirmed in 36
(38%) patients, of whom 5 only had a positive BAL fluid culture
result.
IGRA Results
BAL IGRAs were indeterminate in 32 (34%) patients (Table 2).
Of the 32 indeterminate results, 13 had positive control wells with
#20 SFCs (after subtraction of background), 13 had positive
control wells with less than twice the number of SFCs in the
negative control well, and 6 met both criteria for an indeterminate
result. The proportion of indeterminate results was similar among
TB and non-TB patients (39% vs. 32%, p=0.50). In addition,
there were no differences in gender, age, CD4+ T-lymphocyte
count, anti-retroviral use, or in-hospital mortality in patients with
and without indeterminate BAL IGRAs (p.0.2 for all compar-
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interpretable results. The proportion of positive BAL IGRAs was
similar among patients with a CD4+ T-lymphocyte count #50
cells/ml (15/27, 66%), 51–200 cells/ml (11/18, 61%), and .200
cells/ml (10/15, 67%) (p=0.80). Median SFC counts were
significantly higher in patients with active TB compared to those
without active TB after ESAT-6 (114 vs. 7, p=0.049) but not
CFP-10 (6 vs. 9, p=0.89) stimulation.
Blood IGRAs were less often indeterminate than BAL IGRAs
(14% vs. 34%, difference 220%, 95% CI 233% to 27%,
p=0.002), and 4 of 13 patients with indeterminate blood IGRAs
also had indeterminate BAL IGRAs (Table 2). Blood IGRAs were
Figure 1. Study flow. Of 110 smear-negative tuberculosis suspects referred for bronchoscopy, 104 (95%) underwent the procedure and 94 (85%)
were included in the study. Bronchoalevolar lavage TSPOT and peripheral blood TSPOT provided interpretable results in 62 (66%) and 81 (86%)
patients, respectively.
doi:10.1371/journal.pone.0039838.g001
Table 1. Demographic and clinical characteristics.
Characteristic, N% Total (N=94)
Age (years)
* 34 (28–40)
Female 50 (53%)
Fever 85 (90%)
Weight loss 86 (92%)
Hemoptysis 13 (15%)
Prior active tuberculosis 7 (7.5%)
CD4+ T-lymphocyte count (cells/ml)* 60 (22–200)
Anti-retroviral use 15 (16%)
TB culture-positive 36 (38%)
*Continuous variables presented as medians (interquartile range).
Abbreviations: TB (tuberculosis).
doi:10.1371/journal.pone.0039838.t001
Table 2. BAL and blood IGRA results (N=94).
Blood IGRA BAL IGRA
Negative Positive Indeterminate
Negative 18 13 15
Positive 5 17 13
Indeterminate 2 7 4
Abbreviations: BAL (bronchoalveolar lavage), IGRA (interferon-gamma release
assay).
doi:10.1371/journal.pone.0039838.t002
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including 17 of 37 (46%) patients with positive BAL IGRAs. In 53
patients with interpretable results for both assays, median SFC
counts following ESAT-6 stimulation were higher in BAL IGRAs
than in blood IGRAs overall (11 [IQR 0–167] vs. 1 [IQR 0–16],
p=0.003) and among non-TB patients (3 [IQR 0–90] vs. 0 [IQR
0–2], p=0.001). However, among TB patients, median ESAT-6
SFC counts were not significantly different for BAL and blood
IGRAs (84 [IQR 0–402] vs. 25 [IQR 1–245], p=0.30). The same
patterns were observed following CFP-10 stimulation, with
significant differences in SFC counts between BAL and blood
IGRAs overall (5 [IQR 0–74] vs. 0 [IQR 0–7], p=0.006) and
among non-TB patients (6 [IQR 0–103] vs. 0 [IQR 0–0],
p,0.001), but no significant differences between BAL and blood
IGRAs among TB patients (4 [IQR 0–48] vs. 7 [0–69], p=0.90).
Diagnostic Performance
BAL IGRA sensitivity was 73% (95% CI 50–89%) and
specificity 48% (95% CI 32–64%) in 62 patients with interpretable
results (Table 3). Blood IGRA had similar sensitivity (75%, 95%
CI 57–89%) but higher specificity (78%, 95% CI 63–88%) in 81
patients with interpretable results (Table 4). The specificity
difference was statistically significant (24% vs. 76%, difference
252%, 95% CI 276% to 230%, p,0.001) in 34 non-TB patients
with interpretable results for both assays. In addition, specificity
was similar (56%, 95 CI 30%–80%) when only 16 patients with
a confirmed alternative diagnosis (2 with Pneumocystis jirovecii
pneumonia, 2 with pulmonary kaposi’s sarcoma, and 12 with
bacterial pneumonia) were included in specificity calculations.
Classification of results based on alternative cut-points did not
improve the diagnostic accuracy of BAL IGRA. When using a cut-
point reported for non-commercial ELISPOT-based IGRAs (.2
standard deviations plus 5 SFU above background), BAL IGRA
was negative in 74 (79%) patients. Sensitivity was 31% (95% CI
16–48%) and specificity 85% (95% CI 73–93%). BAL IGRA also
had poor discriminatory ability when results were classified based
on the ratio of SFCs in antigen-stimulated and background wells
(AUC 0.64, 95% CI 0.52–0.75).
Discussion
In this study, we found that BAL IGRA had similar sensitivity
but lower specificity than blood IGRA, and diagnostic accuracy
did not improve with alternate schemes for classification of results.
In addition, approximately one-third of BAL IGRA results were
indeterminate, a significantly higher proportion than for blood
IGRAs. These findings suggest that BAL IGRA performed using
the currently available commercial ELISPOT-based platform is
unlikely to have a role in the diagnosis of smear-negative TB in
hospitalized patients with advanced HIV/AIDS, the population
most likely to have access to such testing in high burden countries.
Our results differ from previous studies of BAL IGRA, which
have largely been conducted in Europe and included mainly
ambulatory patients without HIV infection. In these studies, Jafari
et al reported that the sensitivity of BAL IGRA ranged from 91–
100% and specificity from 80–100%. [8,13,14] Moreover, in-
determinate results were relatively infrequent, occurring in 5–9%
of patients. Potential reasons for the discrepant findings between
these studies and ours include differences in study setting (low- vs.
high-incidence countries), study population (HIV status and
severity of illness), and relative inexperience with performing
BAL IGRA. In the only other study from a high burden country,
Dheda et al found BAL IGRA to have high sensitivity (89%) and
specificity (94%) using a cut-point selected based on ROC analysis,
but results were indeterminate in 34% of patients. [15] Reasons
for the lower specificity observed in our study are unclear but are
consistent with a study reporting detection of M. tuberculosis
antigen-specific T-cells in the BAL fluid of individuals without
active tuberculosis in another high TB burden country. [16] Thus,
as for blood IGRAs, the lower specificity of BAL IGRAs for active
TB in high vs. low TB incidence settings is not surprising.
Similarly, the high proportion of indeterminate BAL IGRA results
in our study and that of Dheda et al is consistent with the higher
proportion of indeterminate results observed in high vs. low TB
incidence settings when IGRAs have been applied to pleural fluid
specimens. [17,18,19].
The large proportion of indeterminate results observed in high
burden countries poses a challenge for a lung-oriented approach to
immunodiagnosis of active pulmonary TB. Based on the criteria
used to categorize blood assays, 19 of 32 (59%) indeterminate BAL
IGRAs in our study could be considered to have a high
background response. For these 19 cases, there were minimal
differences in SFC counts between the negative control well and
the antigen-specific wells. The high background response could be
a result of non-specific immune activation in African populations
as result of chronic exposure to helminths, other infectious agents,
and/or environmental pollutants. [20,21], and may also reflect
HIV-related immune activation However, the interpretation is
limited, as viral load testing was not done and a relationship
between viral load and immune activation could thus not be
established. In addition, non-specific immune activation alone is
Table 3. Diagnostic accuracy of BAL IGRA.
BAL IGRA Culture-positive TB
Yes No
Positive 16 21
Negative 6 19
Sensitivity* 73% (50–89%)
Specificity* 48% (32–64%)
PPV* 43% (27–61%)
NPV* 76% (55–91%)
*% (95% confidence interval); indeterminate IGRA results excluded.
Abbreviations: BAL (bronchoalveolar lavage), IGRA (interferon-gamma release
assay), TB (tuberculosis), PPV (positive predictive value), NPV (negative
predictive value).
doi:10.1371/journal.pone.0039838.t003
Table 4. Diagnostic accuracy of peripheral blood IGRA.
Blood IGRA Culture-positive TB
Yes No
Positive 24 11
Negative 8 38
Sensitivity* 75% (57–89%)
Specificity* 78% (63–88%)
PPV* 69% (51–83%)
NPV* 83% (69–92%)
*% (95% confidence interval); indeterminate IGRA results excluded.
Abbreviations: IGRA (interferon-gamma release assay), TB (tuberculosis), PPV
(positive predictive value), NPV (negative predictive value).
doi:10.1371/journal.pone.0039838.t004
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BAL relative to blood IGRAs. An alternative explanation may be
detection of interferon-gamma secretion by terminally differenti-
ated effector T-cells rather than by MTB-specific effector T-cells.
The accumulation of terminally differentiated effector T-cells is
a hallmark of early immune senescence in advanced HIV/AIDS
[22], and phenotypic studies have suggested that terminally
differentiated effector T-cells may be concentrated at the site of
disease in patients with active TB. [23] Further studies are needed,
as high background responses may represent a potential Achilles
heel for local immunodiagnosis of active TB among patients with
HIV/AIDS living in TB endemic settings.
Our study has several potential limitations. First, our study
population consisted of severely ill, hospitalized patients with
advanced HIV/TB, who may not be representative of the general
population of TB suspects in high-incidence areas. Nevertheless,
our findings are applicable to referral hospitals in sub-Saharan
Africa – the settings most likely to provide bronchoscopy services
in low-income countries. Second, mycobacterial culture on
Lowenstein-Jensen media is an imperfect reference standard. A
more sensitive culture technique (such as liquid culture) and
clinical follow-up may have more accurately classified TB status
and therefore increased the sensitivity and specificity of BAL
IGRA. [24] Finally, the poor performance of BAL IGRA in our
study could be related to technical issues with processing BAL fluid
specimens. The JCRC laboratory that performed this work is the
central laboratory for the National Institutes of Health (NIH)-
funded HIV Vaccine Prevention Trials Network, and JCRC
technicians have more than 10 years of experience performing
ELISPOT assays. Nonetheless, methods for processing BAL fluid
specimens for ELISPOT assays should be standardized to improve
comparability of results across studies.
In summary, BAL IGRA performed poorly for the diagnosis of
smear-negative pulmonary TB in a hospitalized population with
advanced HIV/AIDS. Sensitivity and specificity were inadequate,
and a large proportion of results were indeterminate, mainly due
to high background secretion of interferon-gamma. Further
research on alternative test platforms, biomarkers, and/or antigens
is needed to improve diagnostic accuracy and minimize in-
conclusive results when using a lung-oriented approach to
immunodiagnosis of active pulmonary TB in high burden settings.
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